Primordial, primary, secondary, and tertiary prevention stages for global vascular risk. R. Sacco: Stroke, Volume 38(6).June 2007.1980-1987.

Slides:



Advertisements
Similar presentations
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.
CVD risk estimation and prevention: An overview of SIGN 97.
PAD A Call to Action. PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care.
Etiology Primary hypertension 95% of all cases Secondary hypertension – 5% of all cases – Chronic renal disease – most common White coat hypertension –
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Cholesterol quintile (mg/dL)
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
1 Background Hypertension Type 2 diabetes Coronary heart disease Gallbladder disease Certain cancers Dyslipidemia Stroke Osteoarthritis Sleep apnea Approximately.
Hypertension and Stroke
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Diabetes Disparities & Its Effects on Minority Populations Appathurai Balamurugan, MD, MPH Section Chief, Chronic Disease Epidemiology, ADHHS Assistant.
Chapter 4 Cardiovascular disease
Heart Disease Map.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Hypertension.
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Epidemiology of Stroke Dexter L. Morris, PhD, MD Department of Emergency Medicine University of North Carolina School of Medicine Chapel Hill, NC.
 #1 health concern in USA  38% of all deaths  1 in 2.7 Americans die from CVD  80 million Americans suffer from some form of CVD  Lower educational.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:
Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
MI: Risk Factors and Primary Prevention. Risk Factors Factors that appear to increase the general population’s chances of experiencing a health problem.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.
Risk factors to the Cardiovascular System. Learning Outcomes Describe modifiable risk factors: diet, smoking, activity, obesity Describe non-modifiable.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Cardiovascular Disease in Women Module I: Epidemiology.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
By: David Tran, Mercer University, 2013 Pharm.D. Candidate Prececptor: Dr. Ali Rahimi Morbidity and Mortality Associated with Dyslipidemia.
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Modern Management of Cholesterol in the High-Risk Patient.
CARDIOVASCULAR DISEASE (CVD)
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Acute Stroke: Principles of Modern Management A program of the American Academy of Neurology The AAN Acute Stroke Management courses are supported in part.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Copyleft Clinical Trial Results. You Must Redistribute Slides PRoFESS ® Trial Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS ® )
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.
The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Coronary Heart Disease. Leading Causes of Death Middle age –Sudden death due to heart attack or stroke –Cancer Elderly –Heart disease –Cancer –Stroke.
Stroke John C. Stevenson Editor: Martin Birkhäuser.
 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2007 Hypertension as a Public Health Risk January, 2007.
Chapter 14 Patterns in Health and Disease: Epidemiology and Physiology EXERCISE PHYSIOLOGY Theory and Application to Fitness and Performance, 6th edition.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
© Continuing Medical Implementation ® …...bridging the care gap Geriovascular Prevention Optimizing Prevention of Cardiovascular Disease in the Elderly.
Angela Aziz Donnelly April 5, 2016
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Indication Contraindication Preparation
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Antonio Coca, MD, PhD, FRCP, FESC
What should the Systolic BP treatment goal be in patients with CKD?
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
HDL cholesterol and cardiovascular risk Epidemiological evidence
Prevalence of statin and beta-blocker use by clinical presentation
Presentation transcript:

Primordial, primary, secondary, and tertiary prevention stages for global vascular risk. R. Sacco: Stroke, Volume 38(6).June

Neurovascular Disease  Epidemiology  50% Ischemic stroke, 30% ICH, 20% SAH  Causes/ Pathophysiology  Ethnic Issues  Biology  Sociology

Epidemiology Worldwide Incidence per 100,000 persons/yr; age < 50 yrs  Israel 10.4  Northern Italy 13.6  Spain 13.9  South Africa 33.0  UK women 3.6 Bradley S. Jacobs et al. Stroke 33: , 2002

Risk Factors and Predictors of Stroke Older age Male gender Non-white genetic background Family history Prior stroke or TIA Non-modifiable risk factorsModifiable risk factors Previous TIA or stroke is the most important risk factor for stroke. Hypertension is the most prevalent. Hankey GJ. Cerebrovasc Dis 2003; 16 (Suppl 1): 14–19. Wolf PA. Adv Neurol 2003; 92: 165–172. Sacco et al. Stroke 1997; 28 (7): 1507–1517. Hypertension Diabetes mellitus Atrial fibrillation Carotid artery disease Dyslipidemia Cardiac disease Cigarette smoking Obesity Obstructive Sleep Apnea

Problem! Hispanics have higher prevalence of: Obesity Diabetes Mellitus Hypertension Hyperlipidemia

Prevalence of Identified Risk Factors on Admission to UMC

African-American Hispanic American AgeMenWomen STROKE IN MINORITIES Survey of Stroke Mortality in Texas Rate-Ratio in Comparison to Non-Hispanic Whites Morgenstern et al Stroke, 1997, 28:5-18

Stroke Subtypes in the NOMASS Study F. Rincon et al Cerebrovascular Diseases 2009; 28:65-71.

NOMASS Study F. Rincon et al Cerebrovascular Diseases 2009; 28:65-71.

NOMASS Study

Secondary Stroke Prevention

Problem! Individuals living in the Hispanic Community: Do not know stroke warning symptoms/ signs Do not come to the ED quickly Have less “technical” evaluations

Hypertension

 The most prevalent and modifiable risk factor for stroke  BP reduction lowers stroke recurrence ~28%  Stroke 1997;28:2557  Treatment of elevated SBP in elderly reduces stroke risk by 36%  Decrease in DBP of 5-6 mmHg reduces stroke risk by 42%  Treatment of stage-I hypertension prevents 1 death in 11 patients over 10 years; 1 in 9 if end- organ damage is present

Adjusted Relative Risk of Cardiovascular Mortality According to BP in Men Screened for MRFIT MRFIT, Multiple Risk Factor Intervention Trial Arch Intern Med. 1993;153:186.

“new” Risk Factors for stroke  Abdominal Obesity  Lack of Exercise  Poor Diet  Too Little Alcohol  Too Much Alcohol  Psychosocial Stress  Impoverishment  Genetic  Inflammation  Infectious  PFO  Insulin Resistance  Homocysteinemia  Thrombophilias

Cavernous Malformation

 Prevalence 0.1 to 0.5%  CCM1 – 7q21-q22  CCM2 – 7p13-p15  CCM3 – 3q25.2-q27  CCM1 - krit1: krev interaction trapped 1 protein  CCM2-CCM2 (malcavernin)  CCM3-PDCD10

Re-Search: To Look Again Santiago Ramon y Cajal

Primordial, primary, secondary, and tertiary prevention stages for global vascular risk. R. Sacco: Stroke, Volume 38(6).June

Diet and Exercise

Lipid Levels in Patients Hospitalized with Coronary Artery Disease n = 136,905 Amit Sachdeva et. al. Am Heart J 2009;157:111-7.e2

JUPITER: Cumulative Incidence of Cardiovascular Events NEJM 2008;359:

JUPITER: Effects of Rosuvastatin on Primary End Point by baseline NEJM 2008;359: Primary Endpoints: MI Stroke CVD Unstable Angina Revascularization

Carotid Atherosclerosis

Hansson et al. Nature Reviews Immunology 6, (July 2006) | doi: /nri1882 Atherothrombosis